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Abstract: Tryptophan 2,3-dioxygenase (TDO) is a first and rate-limiting enzyme for the kynurenine pathway of tryptophan metabolism. 
Using Tdo-/- mice, we have recently shown that TDO plays a pivotal role in systemic tryptophan metabolism and brain serotonin synthe-
sis as well as emotional status and adult neurogenesis. However, the expression of TDO in the brain has not yet been well characterized, 
in contrast to its predominant expression in the liver. To further examine the possible role of local TDO in the brain, we quantified the 
levels of tdo mRNA in various nervous tissues, using Northern blot and quantitative real-time RT-PCR. Higher levels of tdo mRNA 
expression were detected in the cerebellum and hippocampus. We also identified two novel variants of the tdo gene, termed tdo variant1 
and variant2, in the brain. Similar to the known TDO form (TDO full-form), tetramer formation and enzymatic activity were obtained 
when these variant forms were expressed in vitro. While quantitative real-time RT-PCR revealed that the tissue distribution of these vari-
ants was similar to that of tdo full-form, the expression patterns of these variants during early postnatal development in the hippocampus 
and cerebellum differed. Our findings indicate that in addition to hepatic TDO, TDO and its variants in the brain might function in the 
developing and adult nervous system. Given the previously reported associations of tdo gene polymorphisms in the patients with autism 
and Tourette syndrome, the expression of TDO in the brain suggests the possible influence of TDO on psychiatric status. Potential 
  functions of TDOs in the cerebellum, hippocampus and cerebral cortex under physiological and pathological conditions are discussed.
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Introduction
Tryptophan and its metabolites, such as kynurenines 
and  serotonin,  are  involved  in  biological  functions, 
such as protein synthesis, energy synthesis, immune 
regulation,  and  higher-order  brain  functioning.1–4 
The mechanisms of mood modulation and disturbance 
that  contribute  to  social  functioning  have  become 
a    particularly  important  issue  in  the  21st  century. 
  Identifying the   mechanisms regulating tryptophan and 
its metabolites in the brain represents a key issue for not 
only understanding the mechanisms   regulating emo-
tion but also   alleviating social   problems. In contrast 
to the systemic   regulation of tryptophan metabolism, 
molecular  mechanisms  and  local  factors  regulating 
tryptophan (kynurenine) metabolism in the brain are 
not  well  understood. There  is  evidence  that,  in  the 
brain, indoleamine 2,3-dioxygenase (IDO),5–9 an initial 
and rate-limiting enzyme for the kynurenine pathway, 
is  markedly  induced  by  immune  signals  (including 
interferon-gamma) and that IDO plays an important 
role in kynurenine production and immune response 
under pathological conditions in vivo and in vitro.6–11 
In  contrast,  under  physiological  conditions,  other 
molecule(s) are likely to play a key role in regulating 
kynurenine metabolism of the adult brain, as IDO lev-
els in the adult nervous systems are extremely low.
A suitable candidate is tryptophan 2,3-dioxygenase 
(TDO),  which  is  another  initial  and  rate-limiting 
enzyme for the kynurenine pathway of tryptophan 
metabolism.1–3,12–15  We  have  previously  studied 
  tdo-deficient  (Tdo-/-)  mice  and  have  demonstrated 
that TDO plays important roles in systemic   tryptophan 
metabolism  and  brain  serotonin  synthesis  as  well 
as modulation of emotional status and adult neuro-
genesis.16 In support of these findings, some genetic 
studies have demonstrated an association of human 
TDO2 single nucleotide polymorphisms (SNPs) with 
psychiatric diseases, such as Tourette syndrome and 
autism.17,18 Moreover, antidepressants have been pos-
tulated to act by directly inhibiting the activity of 
hepatic TDO, thereby enhancing the availability of 
cerebral tryptophan.19,20 These findings demonstrate 
that TDO play an important role not only in systemic 
tryptophan metabolism but also in mood regulation 
and psychiatric disease. However, although TDO is 
predominantly expressed in the liver and a few stud-
ies have suggested that tdo is expressed in the rodent 
or  human  brain,11,21,22  the  precise  distribution  and 
  regulation of local TDO in the brain has not yet been 
well characterized.
Here, we describe the identification, localization 
and regulation of novel tdo variants, which we termed 
tdo variant1 and tdo variant2, in addition to tdo full-
form, during brain development, and in the brain and 
liver of adult mice. The potential roles of TDOs in 
the brain under physiological and pathophysiological 
conditions are also discussed.
Materials and Methods
Animal
Male C57BL/6J mice were purchased from Nippon 
SLC (Hamamatsu, Japan) and maintained as previ-
ously  described.23  Acquisition,  care,  housing,  use, 
and disposition of the animals were in compliance 
with the institutional laws and regulations of Osaka 
University Graduate School of Medicine. All efforts 
were made to minimize both animal discomfort and 
the number of animals used.
cDnA cloning of mouse tdo variants
cDNA cloning of mouse tdo variants was performed 
as previously decribed.23 Briefly, cDNAs were synthe-
sized from adult C57BL/6J mice midbrain and liver 
total RNA using oligo d(T)20 primer and superscript 
III reverse transcriptase. Amplification of mouse tdo 
variants cDNA was done using TaqMan AmpliTaq 
Gold Master Mix and the following primer set: for-
ward primer, 5′-ATCTCTCTCTCCCTCTACTTC- 3′, 
and reverse primer, 5′-TCAATCCGATTCATCGCT 
GC-3′. These primer sequences were designed based 
on the rat tdo minor start site.24 Amplified cDNA frag-
ments (about 1600 bp and 1560 bp) were subcloned 
into pGEM-T easy vector (Promega), which was sub-
jected to sequence analyses.
northern blotting
For Northern blotting, 20 µg of polyadenylated RNAs, 
collected from the liver of 13-week-old male mice, was 
electrophoresed in 1% agarose/2.2 M formaldehyde/1X 
MOPS gel, and blotted onto nylon filter membranes. 
The membranes were UV cross-linked, pre-hybridized 
with hybridization buffer (50% deionized formamide, 
5X SSC, 5X Denhalt’s   solution, 0.1 mg/ml salmon 
sperm DNA and 1% SDS) at 42 °C for 2 h, and subse-
quently hybridized with hybridization buffer contain-
ing 10% dextran sulfate and probes covering the entire TDo and its novel variants in the brain
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region of full-length (36 ∼ 1256), exon 0 (-400 ∼ -15), 
or exon 1 (1∼70) of mouse tdo cDNA-labeled with 
[α-32P] dCTP, washed twice in 2X SSC/0.1% SDS at 
room temperature, and then in 0.2X SSC/0.1% SDS 
for 30 min at 4 °C as previously described.23 The sig-
nals were detected with a BAS 5000 autoradiography 
image analyzer (Fujifilm, Japan).
Quantitative real-time RT-pCR
Total RNAs were purified from tissues (liver,   cerebral 
cortex, hippocampus, pons, striatum, midbrain, and 
cerebellum) of postnatal day 1 to 49. First-strand cDNA 
was prepared from 5 µg of DNase I-treated total RNA; 
quantitative real-time RT-PCR and quantitation of the 
tdo genes were performed as previously described.23 
Briefly, the expression of tdo genes was quantified 
using universal PCR master mix and TaqMan Gene 
Expression assays to amplify mouse tdo exons 4–5 
(thus amplifying full-length tdo as well as tdo variant1 
and variant2) and rodent GAPDH. The expression of 
tdo variants was quantified using Power SYBR Green 
PCR master mix and the following primer sets: tdo 
variant1,  5′-GCACTAAAGTATCTGGGAAGG-3′ 
and  5′-CTCCTTTGCTGGCTCTGTTT-3′;  tdo 
  variant2,  5′-TGTAAGCTGGGTGCTGATTG-3′ 
and 5′-GTGTATCTTTTATGTATCCTG-3′. Real-
time RT-PCR was carried out as described.23 Since the 
expression levels of tdo full-form were much higher 
than those of tdo variant1 and variant2 in all indi-
cated samples examined (for example, the levels of 
tdo   variant1 and varinat2 were about 1% and 0.01% 
compared to those of tdo full-form in the liver, respec-
tively), calculated values of tdo exon 4–5 (reflecting 
the sum of tdo full-form, tdo varinat1 and tdo variant2) 
are nearly identical to the levels of tdo full-form, and 
thus the values are expressed as the levels of tdo full-
form. Results were expressed as the means ± S.E. of 
  duplicate replicates.
TDo enzymatic activity
At 48 h post-Transfection with pCAGGS-tdo, -tdo 
variant1, or -tdo variant2, COS-7 cells were lysed in 
0.02 M phosphate buffer (pH 7.4) containing 2 mM Trp 
and proteinase inhibitor cocktails (Roche   Diagnostics, 
Germany).23 TDO enzymatic activities were assessed 
by  the  conversion  of  Trp  to  Kyn  as  previously 
described.23 TDO specific activities were expressed 
as units (µmoles of Kyn formed per hour at 37 °C) 
per milligram of each protein. The amounts of each 
protein (TDO and its variants) were determined by 
Western blotting using recombinant TDO protein as a 
standard (Geneway Biotech, CA).23 Values represent 
means ± S.E. (n = 5 in each group).
Results
Identification and expression of tdo 
variant1 and variant2 mRnAs, in addition 
to tdo full-form in various nervous tissues
We  first  performed  northern  blot  analyses  using 
a    full-length  tdo  cDNA  probe  to  visualize  all  tdo 
  transcripts in various brain tissues. Liver total RNA 
served as a positive control for northern blot analysis. 
Long exposure film revealed that, in addition to the full-
form size band, lower and higher bands were detected 
in the brainstem, hippocampus, cerebellum, and liver 
(see Fig. 1A in ref. 23). These results suggested that 
novel variants of the tdo gene were present.
To  further  examine  brain  tdo  mRNA  expres-
sion, we next performed quantitative real-time RT-
PCR, using two primer sets, tdo exon 1–2 and exon 
4–5, in order to detect different parts of tdo mRNA. 
Although lower than in the liver, significant levels of 
tdo mRNAs were detected in various brain regions, 
including  the  cerebral  cortex,  striatum,  pons,  and 
midbrain. Consistent with our northern blot findings, 
high expression levels of tdo were detected in the hip-
pocampus and cerebellum. Interestingly, more than a 
10-fold difference was detected in the expression lev-
els of tdo between exon 1–2 and exon 4–5 in the cere-
bral cortex, striatum, cerebellum, pons, and midbrain 
(see Fig. 1B in ref. 23). These findings demonstrate 
that novel variant(s) lacking these regions of exons 
1 and 2 of the tdo gene are present in the brain.
After additional analyses, we identified three forms 
of tdo mRNAs (Fig. 1; see details in ref. 23). One is 
a full-length form corresponding to a traditional tdo 
containing  12  exons.  The  second  is  a  longer  form 
that contains exon 0a + b of the tdo gene, which we 
termed tdo variant1.23 The third is a shorter form that 
  contains exon 0a but lacks exon 1, which we termed 
tdo   variant2.23 To assess the expression of tdo variants, 
we  performed  northern  blot  analyses  using  probes 
  covering different parts of the tdo gene. One is a probe 
covering full-length tdo cDNA, which detects all three 
forms  of  tdo  genes  in  Figure  1.  Second  is  a  probe Kanai et al
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  covering tdo exon 0 (-400 ∼ -15), and thus detects tdo 
variant1 and variant2 but does not detect full-length 
tdo. The last is a probe covering tdo exon 1 (1–70) and 
thus detects both full-length tdo and tdo variant1. As 
previously described in the brain tissues and the liver 
(ref. 23), northern blotting using a probe covering full-
length tdo revealed that at least three tdo mRNAs are 
present in the liver (Fig. 2A). Using a probe covering 
exon 0, we found that tdo mRNA containing exon 0 was 
detected at low levels and its size was nearly identical 
to the full-length tdo mRNA in the liver. As both tdo 
variants contain a part of or whole exon 0, we cannot 
distinguish which variant (or a new variant) is respon-
sible for the band in Figure 2B. But our findings clearly 
demonstrate that one of tdo variants is present and its 
mRNA size is close to that of full-length tdo (Fig. 2B, 
arrows). Using a probe covering exon 1, we detected 
three bands as indicated in Figure 2C. We speculate 
that additional (new) tdo variant(s) containing exon 1 
would be present, as we identified two extra mRNA 
bands containing exon 1 in addition to the band cor-
respond to the full-length tdo in Figure 2C.
Next, to assess the expression of tdo mRNAs in brain 
tissues, we performed quantitative RT-PCR. It revealed 
that both tdo variant1 and variant2 were expressed in 
various  brain  regions,  and  a  relatively  high  expres-
sion of these variants was detected in the hippocam-
pus and cerebellum, in addition to the tdo full-form, as 
  previously described (see Fig. 2 in ref. 23). These results 
suggest that tdo and its two novel variants are expressed 
in   various brain regions, with particularly high levels 
seen in the hippocampus and cerebellum.
Regulation of tdo mRNA expression in 
the hippocampus and cerebellum during 
development
To clarify the regulation of tdo mRNAs in the hippocam-
pus during development, we examined the expression 
of  tdo  mRNAs  in  the  hippocampus  from  postnatal 
day1 (P1) to P49.23 Quantitative RT-PCR revealed that 
1234 56 78 9
1234 56 78 9
0 a2 34 56 78 91 01 11 2
10 11 12
10 11 12
0 a+b
tdo full-form
tdo variant1
tdo variant2
: 100 bp : 400 bp
Figure 1. Schematic structure of the different forms of tdo. The top is a full-length form corresponding to a traditional tdo, which contains 12 exons. The 
middle is a longer form containing exon 0a + b of the tdo gene, which we termed tdo variant1. The bottom is a shorter form containing exon 0a but lacking 
exon 1, which we termed tdo variant2. Coding regions are indicated by black boxes.
A. Exon 1–12 B. Exon 0C . Exon 1
Long Short Long Short Long Short
Figure 2. Expression of tdo mRnAs in the liver. polyadenylated RnAs in the 
liver (20 µg) were hybridized with a specific probe against mouse tdo probes 
covering tdo full-form (exon 1 to exon 12) (A), exon 0 region (B), and exon 
1 (c). Black arrow, full-form tdo. White arrow, tdo variant containing exon 0 
region. Arrowheads, variants of tdo.
Abbreviations: Long, long exposure; Short, short exposure.TDo and its novel variants in the brain
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the levels of tdo full-form were high from P4, when 
the   organization of neural networks begins, and were 
  maintained at the same levels until P49 (levels of tdo 
full-form were calculated from the values of exon 4–5; 
see “Materials and Methods”).23 While expression levels 
of tdo variants were lower than the full-form, expression 
levels of tdo variants gradually increased after P14 in 
the hippocampus (Fig. 3A).23 In the cerebellum, levels 
of tdo full-form were markedly increased at P14, and 
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Figure 3. Regulation of the expression of tdo mRnAs in the hippocampus and cerebellum during development. Quantitative real-time RT-pCR was 
performed for tdo exon 4–5, tdo variant1, and tdo variant2. Total RnAs for postnatal day 1 (p1) to p49 in the hippocampus (A) and cerebellum (B) were 
examined. The level of tdo exon 4–5, tdo variant1, and tdo variant2 in the liver at p49 was assigned an arbitrary value of 106, 60, and 104, respectively. 
Values represent means ± S.e. (n = 5 in each group).
maintained at the same level until P49. In comparison, 
levels of tdo variant2 were low at P1, but were sustained 
at high levels from P4 to P49 (Fig. 3B).23
TDo variant1 and variant2 are functional 
proteins with full-TDo enzymatic activity
We synthesized each protein of TDO and its   variants 
in COS-7 cell lines and analyzed its cell lysates by 
Western blotting using the antibody generated against Kanai et al
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rat purified TDO that can also detect mouse TDO.23 
Western  blotting  of  cell  lysates  revealed  that  the 
molecular weight of mouse TDO full-form and that of 
TDO variant1 was identical.23 In contrast, the molecu-
lar size of variant2 was slightly lower than that of the 
other forms, which fits well with the notion that trans-
lation of tdo variant1 would begin from exon 1, and 
that of variant2 would begin from exon 2, as there is 
no theoretical translation start site in exon 0.
We further examined whether recombinant TDO 
variants form tetramer, since native rat and human 
TDO full-form proteins form a tetramer with heme, 
and tetramer formation is required for TDO full enzy-
matic activity.25 Western blotting showed that recom-
binant mouse TDO full-form migrated as a 44 kDa 
band  at  the  monomer  size  in  SDS-PAGE,  while 
in  Native-PAGE  it  migrated  as  an  approximately 
180 kDa band, which was 4 times higher than mono-
mer size, indicating that it forms tetramer. TDO vari-
ant1 and variant2 were detected as a large complex 
in Native-PAGE, and these molecular weights were 
about 4 times greater than each monomer size, which 
demonstrates that the two novel variants form tetramer 
as well (see Fig. 4 in ref. 23). The enzymatic assays 
for TDOs revealed that all three forms had   similar 
  full-enzymatic activity (Table 1).23 Although further 
work  is  required  in  order  to  examine  the  detailed 
kinetics of these variants, our findings demonstrate 
that these variants are functional proteins with full-
TDO activity.
Discussion
Proper neural network development is important for 
cognitive development, especially in the hippocampus 
and cerebellum. Tryptophan is known to be involved 
in the development of these brain regions and their 
associated cognitive and behavioral functions (Fig. 4). 
For example, tryptophan restriction during early post-
natal  development  reduced  dendrite  arborization, 
spine  density,  and  cell  proliferation  in  the  dentate 
gyrus of the hippocampus, and caused anxiety- and 
depressive-like behavior.26   Furthermore, its metabo-
lite kynurenine, which is produced in   primary neurons 
and glial cells, increases   production of nerve growth 
Hippocampus Cerebellum
a. Trp and hippocampal development
b. Phenotypes of the hippocampus
     in Tdo-/- mice
a. Trp and cerebellar development
b. TDO SNPs associated
     with autism
•  Cell proliferation in the dentate gyrus •  Bergmann glia maturation
•  Granular cell migration
•  Neurogensis and maintenance
•  Mood regulation
•  Dendrite and spine formation
         (Zhang et al, 2006)
(Kanai et al, 2009)
(Nabi et al, 2004)
(Del Angel-Meza et al, 2001)
Hippocampal
neuron
Bergmann glia
Granular
cell
Figure 4. Tryptophan is important for hippocampal and cerebellar development and function. Restriction of tryptophan leads to abnormal development in 
the hippocampus and cerebellum, in turn modulating anxiety-related, depressive-like behaviors and autism.18,26,30 TDo may also contribute to   physiological 
mood regulation via hippocampal neurogenesis, maintenance of neural cells, and early cerebellar development.16,23TDo and its novel variants in the brain
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factor in astrocytes and potentially promotes survival 
of new neurons in the adult hippocampus.2,10,11,27,28
Our previous studies of Tdo-/- mice have demon-
strated the critical role of TDO in hippocampal neuro-
genesis and the maintenance of hippocampal neurons 
as well as in anxiety-related behavior.16 Moreover, 
the expression level of tdo mRNA was significantly 
decreased (over 90%) in the immature dentate gyrus 
of adult alpha-CaMKII hetero-knockout mice, which 
impaired  working  memory  and  mood  regulation.29 
Consistent  with  previous  studies,  our  quantitative 
study demonstrated the expression of TDOs in vari-
ous brain regions, thereby suggesting that TDO and 
its variants, in addition to IDO, potentially produce 
N-formylkynurenine  locally  in  the  nervous  system 
under physiological condition.11,21,23 Collectively, the 
predominant local expression and regulation of full-
form tdo among the various forms in the hippocam-
pus suggests that tdo full-form is the dominant TDO 
form to modulate hippocampal functions including 
mood and memory, and this activity would be medi-
ated by neurogenesis and maintenance of neural cells 
during development and adulthood.
In addition to its role in the hippocampus, trypto-
phan is thought to play an essential role in early cer-
ebellar development. This is based on the finding that 
a tryptophan deficient corn-based diet begun 5 weeks 
before mating leads to the retardation of Bergmann 
glial maturation as well as a concomitant granular cell 
migration.30 Furthermore, it is intriguing that human 
TDO SNPs have been associated with autism,18 and 
that pathological changes have been reported in the 
postmortem cerebellum of the patients with autism 
(Fig. 4).31 Since tryptophan is essential for early cer-
ebellar development and tdo SNPs may be associated 
with autism, local predominant expression and regu-
lation of tdo variant2 in the cerebellum during early 
postnatal development suggests that the tdo variant2, 
in addition to tdo full-form, plays an important role 
in early cerebellar development and may therefore be 
implicated in the development of autism.
In  addition  to  these  roles,  dysregulation  of  the 
kynurenine pathway has been associated with psy-
chiatric  and  neurodegenerative  diseases,  such  as 
depression  and  Alzheimer’s  diseases.2–4  There  are 
some reports that local IDO in the brain represents 
one mechanism of pathology in these disorders, espe-
cially when the immune system is activated.4,7 How-
ever, the presence of different molecular sized TDO 
proteins and altered immunoreactivity against TDO 
has been reported in the frontal cortex of individuals 
with schizophrenia and depression.21 In addition, our 
findings of local expression of TDOs in the cerebral 
cortex suggests a local role of TDO and its variants 
in  the  specific  regional  modulation  of  tryptophan 
metabolism and subsequent behavioral and immune 
modulation, which would likely be regulated via a 
different mechanism from IDO under such pathologi-
cal conditions.
In summary, in addition to the liver TDO, we pres-
ent evidence that TDO, as well as newly identified 
TDO variants, are locally expressed and regulated in 
the brain, and therefore may play a critical role in the 
hippocampal and cerebellar development and func-
tion (Fig. 5).
Dysregulation  of  brain  or  liver  TDOs  may  be 
involved in psychiatric or neurodegenerative disorders 
such as anxiety-related disorders, autism, or multiple 
sclerosis.  Further  analyses  of  brain  cells  express-
ing newly identified TDO variants in addition to the 
TDO full-form, the possible identification of new tdo 
variant(s), and the elucidation of the regulation and 
roles of these molecules may open a new avenue for 
understanding the role of tryptophan metabolites in 
higher-order brain functions in the future.
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